Issue: June 2015
May 06, 2015
1 min read
Save

Angio-OCT may have utility in visualizing choroidal neovascularization

Issue: June 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

DENVER — Angio-OCT may be a novel diagnostic technique to image patients with age-related macular degeneration or inflammatory infections, according to a presentation here.

In a poster presented at the Association for Research in Vision and Ophthalmology annual meeting, Vittoria Ravera, MD, and colleagues evaluated the visibility of choroidal neovascularizations in a comparison of angio-OCT imaging, fluorescein angiography and indocyanine green angiography.

Of 20 eyes, 13 displayed occult choroidal neovascularization, four had classic choroidal neovascularization, two presented a combination of occult and classic choroidal neovascularizations, and one had retinal angiomatous proliferation.

The choroidal neovascularization complex was visible in 99% of cases with indocyanine green angiography, but precise characterization of the vessels from the lesion was visible in only 30% of eyes.

The choroidal neovascularization complex was visible in 100% of eyes with angio-OCT, and there was better identification of the neovascular network, the study said.

Imaging was not limited by subretinal fluid or blood, while pigmented epithelium detachment formed mild masking in the images, the study said.

“What is important is that compared to fluorescein angiography, you can have a better visualization of the choroidal neovascularization, whereas the image is much more similar to the one on indocyanine green angiography,” Ravera told Ocular Surgery News. “But importantly, you can see dynamic features or functional features such as activity or leakage. So, it can be of great help maybe in a complementary analysis, not alone or substituting one or the other.” - by Kristie L. Kahl

Disclosure: Ravera reports no relevant financial disclosures.